Ipca Laboratories Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/g6hvdmp51ph5yvaepgerbn3m.pdf

Key Takeaways


Domestic Formulation: The Core Growth Engine


Unichem: The Margin Recovery Story

Harish Kamath: "In the existing molecule also, we will recover our market share, whatever we have lost, albeit at a lower price. Plus new products also, they continue to launch in the marketplace."

Export Formulations: West Africa Leads

Ajit Kumar Jain: "That business was fiercely competitive. And practically, in that market, there was a blood bath on pricing vertically. A lot of products we're selling at losses in that market."

Margin Architecture: Mix Shift at Work


U.S. Business: Ipca Portfolio Builds, Unichem Resets

Harish Kamath: "whatever five products I am today marketing, it is almost now 2 years and now we have reached a market share. Most of the molecule is 25% plus because they are all our backward-integrated molecules."

Biosimilars & Other Initiatives

Ajit Kumar Jain: "We have already taken opinion on our regulatory framework from U.K. MHRA. We have taken from European authorities and also from U.S. FDA. So all the three agencies, we have taken that opinion on protocols and everything. So everything is going on in that line."

Guidance & Commitments

CommitmentSpecificsTimeline
Unichem U.S. market share lossDecline to continue before recovery begins1-2 more quarters
Unichem EBITDA margin targetReach ~15%2-3 years
Unichem EBITDA margin targetGradually improve to ~20%As European filings/registrations come in
Unichem stand-alone portfolio growth7-8% annuallyOnce market share loss regained
Ipca U.S. product launches4-5 more molecules launchedNext 6-12 months
Ipca U.S. commercialization5-7 molecules commercializedNext 12-15 months
Ipca U.S. annual filings~5-6 filings every yearOngoing
Domestic business growth~10-12%Longer period
Overall company growth~10-11%Longer period
EBITDA margin improvement150 bps+ per year; 300 bps potentialNext 2 years, if 10-11% growth holds
Full-year material cost improvement~3.3-3.4% reduction in material cost-to-sales ratioFY26
Detailed business and margin guidanceTo be providedAfter budget exercise completes by March

Key Metrics

MetricQ3 FY26
Consolidated revenue₹2,245 cr, growth of ~6.5% YoY from ₹2,393 cr
Consolidated revenue (9M FY26)₹7,258 cr, growth of ~8.44% YoY from ₹6,993 cr
Stand-alone EBITDA margin26.09%, improved ~1.81 ppt YoY from 24.25%
Consolidated EBITDA margin~22.5%, improved ~2.28 ppt YoY from 19.87%
Consolidated EBITDA margin (9M FY26)20.79%, improved ~1.61 ppt YoY from 19.18%
Stand-alone material cost-to-sales ratio~24%, improved ~3.64 ppt YoY
Stand-alone material cost-to-sales ratio (9M FY26)25.37%, improved ~3.36 ppt YoY from 28.73%
Domestic formulation growth~12% YoY
Export formulation growth~17% YoY
API business revenue~₹317 cr, flat YoY
API business growth (9M FY26)~14% YoY to ~₹1,051 cr from ₹924 cr
Unichem EBITDA margin~8%
Unichem overall revenue growth target8% to 10% over next 2 to 3 years
Unichem EBITDA margin target~15% in 2 to 3 years, gradually improving to ~20%
Ipca U.S. business (Ipca + Unichem consolidated)~₹395 cr, growth of ~17% YoY from ~₹339 cr
Ipca-manufactured U.S. portfolio (5 products, 9M FY26)~₹1 cr to ₹1.1 cr
Ipca U.S. filings in current year4 filings, annual run-rate of ~5 to 6 filings
Promotional branded business growth outlook~10% to 12% over longer period
Overall company growth outlook~10% to 11%
EBITDA margin improvement outlook1.5%+ per year if top line growth is ~10% to 12%